MET在癌症发生发展及治疗中的不同作用
The Different Roles of MET in the Development and Treatment of Cancer.
作者信息
Mollerup Jens, Jørgensen Jan Trøst
机构信息
Pathology Division, Agilent Technologies Denmark ApS, Produktionsvej 42, 2600 Glostrup, Denmark.
Department: Medical Sciences, Dx-Rx Institute, Baunevaenget 76, 3480 Fredensborg, Denmark.
出版信息
Cancers (Basel). 2023 Oct 21;15(20):5087. doi: 10.3390/cancers15205087.
Abstract
This Special Issue features contributions from leading international researchers in the field of MET (hepatocyte growth factor (HGF) receptor) biology and therapeutics [...].
摘要
本期特刊收录了MET（肝细胞生长因子（HGF）受体）生物学与治疗领域国际顶尖研究人员的投稿[……]
相似文献
1
The Different Roles of MET in the Development and Treatment of Cancer.MET在癌症发生发展及治疗中的不同作用
Cancers (Basel). 2023 Oct 21;15(20):5087. doi: 10.3390/cancers15205087.
2
The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment.肝细胞生长因子（HGF）-MET通路抑制剂在癌症治疗中的潜在作用。
Onco Targets Ther. 2014 Jun 11;7:969-83. doi: 10.2147/OTT.S40241. eCollection 2014.
3
Biological roles of hepatocyte growth factor-Met signaling from genetically modified animals.来自基因改造动物的肝细胞生长因子- Met信号通路的生物学作用
Biomed Rep. 2017 Dec;7(6):495-503. doi: 10.3892/br.2017.1001. Epub 2017 Oct 18.
4
Targeting the hepatocyte growth factor/Met pathway in cancer.靶向癌症中的肝细胞生长因子/Met通路。
Biochem Soc Trans. 2017 Aug 15;45(4):855-870. doi: 10.1042/BST20160132. Epub 2017 Jul 3.
5
Expression of hepatocyte growth factor and its receptor met in Wilms' tumors and nephrogenic rests reflects their roles in kidney development.肝细胞生长因子及其受体Met在肾母细胞瘤和肾源性残留中的表达反映了它们在肾脏发育中的作用。
Clin Cancer Res. 2009 Apr 15;15(8):2723-30. doi: 10.1158/1078-0432.CCR-08-1898. Epub 2009 Mar 24.
6
Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.肺癌中靶向HGF/c-Met轴的药物研究现状
Cancers (Basel). 2018 Aug 21;10(9):280. doi: 10.3390/cancers10090280.
7
Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting.针对 HGF/c-MET 靶向的卵巢癌治疗策略。
Medicina (Kaunas). 2022 May 11;58(5):649. doi: 10.3390/medicina58050649.
8
Hepatocyte growth factor/MET in cancer progression and biomarker discovery.肝细胞生长因子/间质上皮转化因子在癌症进展及生物标志物发现中的作用
Cancer Sci. 2017 Mar;108(3):296-307. doi: 10.1111/cas.13156.
9
Structural and Functional Insight Into the Glycosylation Impact Upon the HGF/c-Met Signaling Pathway.糖基化对HGF/c-Met信号通路影响的结构与功能洞察
Front Cell Dev Biol. 2020 Jun 18;8:490. doi: 10.3389/fcell.2020.00490. eCollection 2020.
10
Hepatocyte growth-factor and its receptor C-met regulate both cell-growth and invasion of human pancreatic-cancer.肝细胞生长因子及其受体C-甲硫氨酸调节人类胰腺癌的细胞生长和侵袭。
Int J Oncol. 1995 Oct;7(4):877-81. doi: 10.3892/ijo.7.4.877.
本文引用的文献
1
Targeting Amplification: Opportunities and Obstacles in Therapeutic Approaches.靶向扩增：治疗方法中的机遇与障碍
Cancers (Basel). 2023 Sep 14;15(18):4552. doi: 10.3390/cancers15184552.
2
A Systematic Review of Mesenchymal Epithelial Transition Factor () and Its Impact in the Development and Treatment of Non-Small-Cell Lung Cancer.间充质上皮转化因子（）及其在非小细胞肺癌发生发展与治疗中作用的系统评价
Cancers (Basel). 2023 Jul 27;15(15):3827. doi: 10.3390/cancers15153827.
3
The Development and Role of Capmatinib in the Treatment of MET-Dysregulated Non-Small Cell Lung Cancer-A Narrative Review.卡马替尼在治疗MET失调的非小细胞肺癌中的发展与作用——一篇叙述性综述
Cancers (Basel). 2023 Jul 10;15(14):3561. doi: 10.3390/cancers15143561.
4
The Role of MET in Resistance to EGFR Inhibition in NSCLC: A Review of Mechanisms and Treatment Implications.MET在非小细胞肺癌对表皮生长因子受体抑制的耐药中的作用：机制及治疗意义综述
Cancers (Basel). 2023 May 31;15(11):2998. doi: 10.3390/cancers15112998.
5
Overview of Molecular Detection Technologies for in Lung Cancer.肺癌分子检测技术概述
Cancers (Basel). 2023 May 26;15(11):2932. doi: 10.3390/cancers15112932.
6
The Role of cMET in Gastric Cancer-A Review of the Literature.cMET在胃癌中的作用——文献综述
Cancers (Basel). 2023 Mar 26;15(7):1976. doi: 10.3390/cancers15071976.
7
MET Amplification as a Resistance Driver to TKI Therapies in Lung Cancer: Clinical Challenges and Opportunities.MET扩增作为肺癌中TKI治疗的耐药驱动因素：临床挑战与机遇
Cancers (Basel). 2023 Jan 18;15(3):612. doi: 10.3390/cancers15030612.
8
Rilotumumab Resistance Acquired by Intracrine Hepatocyte Growth Factor Signaling.通过内分泌肝细胞生长因子信号传导获得的瑞罗西单抗耐药性。
Cancers (Basel). 2023 Jan 11;15(2):460. doi: 10.3390/cancers15020460.
9
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLC.纵向血浆蛋白质组学衍生的生物标志物可预测MET失调的非小细胞肺癌对MET抑制剂的反应。
Cancers (Basel). 2023 Jan 1;15(1):302. doi: 10.3390/cancers15010302.
10
Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review.赛沃替尼治疗MET改变的非小细胞肺癌的研发概况——一篇叙述性综述
Cancers (Basel). 2022 Dec 12;14(24):6122. doi: 10.3390/cancers14246122.
Zotero 插件